Gilead Sciences' move to launch generic versions of two hepatitis C treatments could motivate states to eliminate restrictions on their Medicaid and inmate populations.
Gilead will start selling the generics for chronic hepatitis C in January at a $24,000 list price, a significant discount compared to the price for its branded alternatives, which can cost nearly $100,000 for a full course of treatment.
Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors.
Senate Majority Leader Mitch McConnell last week unveiled a bill that would prevent a government shutdown and provide more than $1 billion to battle the Zika virus.
There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.
Spending on prescription drugs under the Medicare Part D program increased more than 17% in 2014 despite a claims increase of just 3%, and other news
The CMS shared the numbers in its second annual Part D data dump, which comes as rising drug costs have drawn widespread criticism. Under Medicare Part D in 2014, doctors wrote more than 1.4 billion prescriptions, together costing the program and beneficiaries more than $121 billion.
Drugmaker Gilead Sciences saw its earnings fall again amid lower sales of its expensive blockbuster hepatitis C drug Harvoni.
It will soon be easier for Medicaid beneficiaries in Massachusetts to get hepatitis C medications thanks to a new drug rebate program.
Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
Corporate CEOs, attorneys, real estate moguls and other business leaders routinely serve on the boards of not-for-profit hospitals, systems and insurers. But some top executives at not-for-profit healthcare organizations also hold board seats at some of the largest publicly traded companies in the...
Institutional investors are pushing for a range of reforms at publicly traded healthcare firms. High on the agenda is easier access to proxy ballots for an alternative slate of board directors.
Biologic drugmaker Gilead Sciences is buying a subsidiary of Nimbus Therapeutics and its experimental medicine for an increasingly prevalent metabolic disorder that causes dangerous fat buildup in the liver.